Evofem Biosciences (EVFM) Misses Q2 EPS by 54c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Evofem Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 4, 2020 8:00 AM EDTSAN DIEGO, Aug. 4, 2020 /PRNewswire/ --Â Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a commercial stage biopharmaceutical company, today reported financial results for the three- and six- month periods ended June 30, 2020.
... More
